Creasallis
Creasallis is the Creative Antibody Solutions Company. Our debut technology is a way to improve the penetration of antibody based drugs into the tumour, through our single plug and play technology. Our technology can be applied to any antibody based therapeutic.
Creasallis are winners of the 2021 Accelerate@Babraham accelerator programme and have since raised a VC lead pre-seed round. They are currently tenants at the Babraham Research Campus. We are also winners of startup business of the year 2023 in the CambridgeLive Business awards. Our mission is to solve antibody bottlenecks in therapeutics with simple innovative solutions. We have a world class experienced team in the antibody therapeutics space who are ready to disrupt this space!
